Tag
AstraZeneca uses AI to generate and rank protein candidates, integrating models with experiments and robotics to speed up biologic drug discovery and tackle previously undruggable targets.
AI is accelerating biologic drug design by predicting candidate molecules and enabling multi-target therapies, with potential to cut discovery timelines by 50% and target previously undruggable diseases.
The FDA has cleared a second species of carcass-eating fly, Lucilia cuprina, for maggot wound therapy, marketed as MediFly Maggots by Cuprina Holdings, expanding options for maggot debridement therapy.